Novavax (NVAX) Stock Upgraded to Buy - $101 Price Target

June 29, 2020 - Shares of Novavax (NVAX) have been upgraded to buy with a $101 price target at H.C Wainwright.  The firm sees the Covid-19 vaccine NVX-CoV2373 potentially doing $400 million in annual sales. 

Novavax (NVAX) stock was just $5 in early 2020 but has soared to new heights in the last few months.  NVAX has been public for nearly 25 years but has always been a failure.  Could this time be different?

Keep an eye on the Lemonade (LMND) IPO coming this week - https://daytradingstockblog.blogspot.com/2020/06/lemonade-lmnd-stock-ipo-ai-bots-replace.html

Novavax NVAX Stock Analysis August 31 2009

The following is a Novavax Inc ( NVAX ) stock technical analysis for August 31, 2009

Novavax Inc. Support & Resistance Levels - 8/31/09

Resistance Levels: $6.00, $6.30, $8

Support Levels: $5.49, $5.00

Chart - http://stockcharts.com

Discuss Stocks - http://stockstobuy.org

Novavax, Inc. (NVAX) continues to run up on swine flu news as this company could have a promising H1N1 vaccine. Support for the stock is currently located at $5.50 with pullbacks below the 10 day moving average becoming a strong buy. On the upside, NVAX has been having trouble closing over $6 where there is major selling Resistance. A close over $6 would be very bullish!

For More Technical Analysis - Go Here

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Novavax NVAX Stock Surges on H1N1 Swine Flu Goal

August 5, 2009 - Shares of Novavax, Inc. (NVAX) are surging Up 22% to $5.65 this morning as the company is reporting substantial news on their swine flu vaccine. There is not much resistance until the $7's while support is at $5

NVAX News 8/5/09

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

cGMP quality material produced in 11 weeks from strain availability

Novavax, Inc. (Nasdaq: NVAX) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary, novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world's influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries. Full Article

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Novavax NVAX Stock News 6/4/09 June 4 2009

Novavax, Inc. (NVAX), the orignal swine flu momentum stock, is rising today ( $2.60 ) on follow up news on their H1N1 vaccine. Discuss NVAX - Discuss stocks - http://stockstobuy.org


Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate against the Novel Influenza A (H1N1) Virus

Company completes initial steps towards producing Influenza A (H1N1) VLP vaccine
for animal and human testing


Novavax, Inc. (NASDAQ: NVAX) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) have signed an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced influenza A (H1N1) VLP vaccine against the strain recommended by the Centers for Disease Control and Prevention (CDC).

http://www.novavax.com/download/releases/H1N1FO21.pdf

For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE

Novavax NVAX Stock 4/28/09 April 28 2009

The following is a Novavax Inc ( NVAX ) stock technical analysis for April 28, 2009

Novavax Inc. Support & Resistance Levels - 4/28/09

Resistance Levels: $3.15, $3.50, $3.88, $4.35-$4.38

Support Levels: $2.50, $1.93

http://stockcharts.com

As you probably know, Novavax ( NVAX ) stock is rising due to the swine flu outbreak. From a technical analysis point of view, NVAX has solid support at the $2.50 level. NVAX closed just above this level on Monday and is now rising back near $3 in pre market trading. There is some nice resistance between $3-$3.15 but then nothing until around $3.30 and then $3.50. If the $3.88 high from Monday is broken, I think NVAX could probably trade up to $4.33-$4.38 area which is a major resistance level. You have big funds that have been trapped in this stock for years waiting to unload in the $4's. It would take a huge outbreak in the swine flu or an actual announcement on a drug to get through this level. Three years ago NVAX was trading at $8 on avian bird flu fears. A close below $2.50 would most likely take NVAX stock back to the 200 day moving average. Come Join the NVAX discussion.

For More Technical Analysis - Go Here

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free